Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En observationsundersøgelse for at evaluere effektiviteten og sikkerheden af ​​Avelumab + Axitinib-kombination hos deltagere med aRCC (AVION)

20. maj 2026 opdateret af: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Evaluering i den virkelige verden af ​​effektivitet og sikkerhed med Avelumab (BAVENCIO®) + Axitinib (INLYTA®) hos patienter med aRCC i flere EU-lande (AVION)

Hovedformålet med denne undersøgelse er at udvide viden om effektiviteten af ​​Avelumab intravenøs infusion i kombination med Axitinib som førstelinjebehandling til deltagere med fremskreden nyrecellekarcinom (aRCC) ud over sikkerheden og tolerabiliteten under daglige rutineforhold. klinisk praksis.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

105

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Belgien
      • Bonheiden, Belgien
        • Imelda Ziekenhuis
      • Brasschaat, Belgien
        • AZ Klina
      • Bruges, Belgien
        • AZ Sint-Jan
  • Grækenland
      • Athens, Grækenland
        • Gen. Hos. "Alexandra"
      • Athens, Grækenland
        • General Hospital of Athens G.Gennimatas
      • Athens, Grækenland
        • Henry Dunant Hospital Center
      • Athens, Grækenland
        • University Hospital of Athens Sotiria
      • Attiki, Grækenland
        • Attikon Hospital
      • Chaïdári, Grækenland
        • Attikon
      • Heraklion, Grækenland
        • General Hospital "Venizelio"
      • Ioannina, Grækenland
        • University Hospital of Ioannina
      • Kavala, Grækenland
        • Kavala General Hospital
      • Larissa, Grækenland
        • University Hospital of Larissa
      • Piraeus, Grækenland
        • Metaxa Hospital
      • Piraeus, Grækenland
        • Metropolitan Hospital Greece
      • Pátrai, Grækenland
        • General Hospital of Patras "o Agios Andreas"
      • Thessaloniki, Grækenland
        • Papageorgiou Hospital
      • Thessaloniki, Grækenland
        • Agios Loukas Hospital
      • Thessaloniki, Grækenland
        • Bioclinic (GRC)
      • Thessaloniki, Grækenland
        • Saint Luke Hospital
  • Rusland
      • Irkutsk, Rusland
        • Regional Oncology Dispensary - Irkutsk
  • Tyskland
      • Amberg, Tyskland
        • Klinikum St. Marien Amberg
      • Aschaffenburg, Tyskland
        • Klinikum Aschaffenburg Medizinische Klinik
      • Berlin, Tyskland
        • Zentrum für urologische Onkologie
      • Biberach an der Riss, Tyskland
        • Biberach
      • Bielefeld, Tyskland
        • Evangelisches Klinikum Bethel
      • Bielefeld, Tyskland
        • Evangelisches Krankenhaus Bielefeld
      • Braunschweig, Tyskland
        • Urologie im Schlosscarree
      • Deggendorf, Tyskland
        • Donauisar Klinikum Deggendorf
      • Dresden, Tyskland
        • Urologische Gemeinschaftspraxis
      • Eisenach, Tyskland
        • St. Georg Klinikum Eisenach gGmbH
      • Erlangen, Tyskland
        • Universitätsklinikum Erlangen
      • Essen, Tyskland
        • Universitaetsklinikum Essen Uroonkologie
      • Friedrichshafen, Tyskland
        • Klinikum Friedrichshafen GmbH daVinci® -Zentrum Bodensee
      • Fürth, Tyskland
        • Onkologische GP Dres. Wilke/Wagner/Petzoldt
      • Fürth, Tyskland
        • Onkologische SP Praxis Fürth
      • Goslar, Tyskland
        • MVZ Onkologische Kooperation Harz GbR
      • Halberstadt, Tyskland
        • Praxis Dr. Maas
      • Hamburg, Tyskland
        • Universitätsklinikum Hamburg-Eppendorf
      • Hanover, Tyskland
        • Medizinische Hochschule Hannover
      • Hanover, Tyskland
        • Vinzenzkrankenhaus Hannover
      • Heinsberg, Tyskland
        • Praxis Kretz
      • Jena, Tyskland
        • Universitätskinderklinik Jena
      • L.-Eisleben, Tyskland
        • Urologische Praxis Dr. Ralf Eckert
      • Luckenwalde, Tyskland
        • Urologische Praxis Dipl.-Med. Susanne Kloß
      • Lübeck, Tyskland
        • Universitatsklinik Schleswig-Holstein
      • Magdeburg, Tyskland
        • Schwerpunktpraxis für Hämatologie und Onkologie
      • Minden, Tyskland
        • Johannes Wesling Klinikum Minden der Mühlenkreiskliniken (AöR)
      • Münster, Tyskland
        • University of Munster
      • Münster, Tyskland
        • Uniklinikum Münster
      • Osnabrück, Tyskland
        • Marienhospital Osnabrück - Standort Natruper Holz
      • Osnabrück, Tyskland
        • Paracelsus Klinik Osnabrück
      • Osnabrück, Tyskland
        • Klinikum Osnabrück GmbH
      • Ostfildren, Tyskland
        • medius Klinik Ostfildern-Ruit
      • Rostock, Tyskland
        • Wissenschaftskontor Nord GmbH & Co. KG
      • Rüsselsheim am Main, Tyskland
        • GPR Klinikum Rüsselsheimg GmbH
      • Sigmaringen, Tyskland
        • SRH Kliniken Landkreis Sigmaringen (DEU)
      • Stolberg, Tyskland
        • Hämatologie und Onkologie Stolberg
      • Troisdorf, Tyskland
        • Praxis Troisdorf
      • Westerstede, Tyskland
        • Medizinische Studiengesellschaft Nord-West GmbH
      • Wetzlar, Tyskland
        • Lahn Dill Kliniken GmbH

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Deltagere med en bekræftet diagnose af fremskreden RCC vil blive observeret i denne undersøgelse.

Beskrivelse

Inklusionskriterier:

  • Deltagere med Eastern Cooperative Oncology Group (ECOG) præstationsstatus 0, 1 eller 2
  • Deltagere med en histologisk bekræftet diagnose af RCC af enhver histologisk oprindelse
  • Deltagere med en lokalt fremskreden/metastatisk sygdom (dvs. [dvs.] nydiagnosticeret Stage 4 RCC pr. American Joint Committee on Cancer) eller har tilbagevendende sygdom
  • Deltagerne har modtaget 1 eller 2 cyklusser af Avelumab plus Axitinib-behandling som en førstelinjebehandling i henhold til det godkendte produktresumé (SmPC)
  • Deltagere, der er villige til at underskrive den skriftlige informerede samtykkeformular (ICF) for at deltage i denne undersøgelse

Ekskluderingskriterier:

  • Deltagere med kontraindikationer for Avelumab eller Axitinib i henhold til det godkendte produktresumé
  • Deltagere, der har deltaget i ethvert interventionelt klinisk studie af et lægemiddel eller en enhed inden for 28 dage før starten af ​​Avelumab plus Axitinib

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Avelumab + Axitinib
Der vil ikke være nogen undersøgelsesspecifikke interventioner i denne undersøgelse. Deltagere med fremskreden RCC, der modtager 800 milligram (mg) Avelumab intravenøst ​​hver 2. uge i kombination med 5 mg Axitinib oralt to gange dagligt i overensstemmelse med betingelserne for markedsføringstilladelsen for førstelinjebehandlingen i henhold til den nuværende kliniske praksis, vil blive observeret. i 24 måneder i denne undersøgelse.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall Survival Rate
Tidsramme: At 12 months after index date (baseline visit as reported in the electronic case report form [eCRF])
Overall survival rate was defined as the percentage of participants who are alive at 12 months after the index date. Percentage of participants alive at the time of outcome assessment (12 months) were calculated as per the Kaplan-Meier (KM) approach. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
At 12 months after index date (baseline visit as reported in the electronic case report form [eCRF])

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Overall Survival Rate
Tidsramme: At 24 months after index date (baseline visit as reported in the eCRF)
Overall survival rate was defined as the percentage of participants who are alive at 24 months after the index date. Percentage of participants alive at the time of outcome assessment (24 months) were calculated as per the Kaplan-Meier (KM) approach. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
At 24 months after index date (baseline visit as reported in the eCRF)
Duration of Overall Survival
Tidsramme: From the index date (baseline visit as reported in the eCRF) to the date of death from any cause, (assessed up to 24 months after index date)
Duration of overall survival is defined as the time from index date to the date of death due to any cause. The overall survival was analyzed by using the Kaplan-Meier method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of death from any cause, (assessed up to 24 months after index date)
Objective Response Rate (ORR) Assessed by Investigator up to 24 Months After the Index Date
Tidsramme: up to 24 months after the index date (baseline visit as reported in the eCRF)
Objective response rate was defined as percentage of participants with either a confirmed complete response (CR) or partial response (PR) as best overall response up to 24 months after the index date. CR: Disappearance of all target and non-target lesions. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum of their diameters, and no unequivocal progression of non-target lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Disease Control Rate (DCR) Assessed by Investigator up to 24 Months After the Index Date
Tidsramme: up to 24 months after the index date (baseline visit as reported in the eCRF)
Disease control rate is defined as the percentage of participants with objective response (complete response [CR] or partial response [PR] or stable disease [SD]) as best overall response up to 24 months after the index date. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD while on study. PD is defined as at least a 20 % increase in the SLD of target lesion, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Duration of Response (DoR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Tidsramme: up to 24 months after the index date (baseline visit as reported in the eCRF)
DoR was defined for participants with objective response, as the time from first documentation of objective response (Complete Response [CR] or Partial Response [PR]) to the date of first documentation of progression disease (PD) or death due to any cause, whichever occurred first. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at least a 20% increase in the SLD, taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
up to 24 months after the index date (baseline visit as reported in the eCRF)
Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 Assessed by Investigator
Tidsramme: From the index date (baseline visit as reported in the eCRF) to the date of disease progression or death from any cause, whichever occurred first (assessed up to 24 months after index date)
PFS time was defined as the time from index date to the date of the first documentation of objective progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST version 1.1, PD was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions was also considered PD. The tumor response was determined according to RECIST version 1.1 and assessed by the investigator. PFS was calculated based on KM method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of disease progression or death from any cause, whichever occurred first (assessed up to 24 months after index date)
Progression-free Survival 2 (PFS2) According to RECIST Version 1.1 Assessed by Investigator
Tidsramme: From the index date (baseline visit as reported in the eCRF) to the date of disease progression on second-line treatment or death from any cause, whichever occurred first (assessed up to 24 months after index date)
PFS2 was defined as time interval from the index date to the date of disease progression on second-line treatment or death from any cause, whichever occurred first. Per RECIST version 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The tumor response will be determined according to RECIST version 1.1 and assessed by the investigator. PFS2 was calculated based on Kaplan Meier method. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) to the date of disease progression on second-line treatment or death from any cause, whichever occurred first (assessed up to 24 months after index date)
Change From Baseline in National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy-Kidney Symptom Index 19 (NCCN-FACT FKSI-19) Total Score
Tidsramme: Index date (baseline visit as reported in the eCRF), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102 and 104 weeks
NCCN-FACT FKSI-19, a validated, disease-specific questionnaire for RCC. It includes 19 items across four domains, Disease-Related Symptoms-Physical (DRS-P), Disease-Related Symptoms-Emotional (DRS-E), Treatment Side Effects (TSE), and Functional Wellbeing (FWB), based on symptoms experienced over past 7 days. Responses were recorded on 5-point Likert scale (0 = not at all to 4 = very much), yielding a total score from 0 to 76, higher scores reflecting better quality of life. A negative mean change in score indicated worsening condition. Domain score ranges and directionality: DRS-P: 0-48, higher scores = fewer physical symptoms; DRS-E: 0-4, higher = fewer emotional symptoms; TSE: 0-12, higher = more severe side effects; FWB: 0-12, higher = better functional wellbeing. As per NCCN-FACT FKSI-19 scoring guidelines, the total Health-related quality of life (HRQoL) score (range 0-76) was calculated as sum of single items scores multiplied by 19 and divided by the number of items completed.
Index date (baseline visit as reported in the eCRF), at 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72, 78, 84, 90, 96, 102 and 104 weeks
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs, TEAEs Leading to Permanent Treatment Discontinuation and TEAEs Leading to Death According to Medical Dictionary for Regulatory Activities (MedDRA)
Tidsramme: From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs. Treatment-related TEAEs is defined as reasonably related to the study intervention. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Number of Participants With Adverse Events Based on Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0
Tidsramme: From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Severity of TEAEs were evaluated using the NCI-CTCAE version 5.0. The grade are as follows: grade 1 : mild grade 2 : moderate grade 3 : severe or medically significant but not immediately life-threatening grade 4 : life threatening or disabling grade 5 : death related to AE. Number of participants with TEAEs grade greater than or equal to (>=) 3 were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 90 days post discontinuation of avelumab plus axitinib or completion of the 24 months (i.e., end of the study) follow-up from the index date, whichever occurred first
Time to Therapy Discontinuation Due to AE Greater Than or Equal to (>=) Grade-3
Tidsramme: From the index date (baseline visit as reported in the eCRF) up to 24 months
Time to therapy discontinuation due to AE >= grade 3 was reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From the index date (baseline visit as reported in the eCRF) up to 24 months
Duration of Avelumab Plus Axitinib Therapy Among Participants Who Discontinued the Axitinib Due to All-Cause AEs >= Grade 3
Tidsramme: Time from first dose of study drug up to 24 months
The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC. Duration of Avelumab plus Axitinib therapy (days) = (Date of discontinuation of Axitinib - Date of index date + 1). Duration of avelumab plus axitinib therapy among participants who discontinued the Axitinib due to all-cause AEs >= grade 3 was reported.
Time from first dose of study drug up to 24 months
Time to Onset of Treatment - Emergent Adverse Events (TEAEs)
Tidsramme: From index date (baseline visit as reported in the eCRF) up to 24 months
Time to onset of TEAE = Start date TEAE - Index date. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Duration of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: From index date (baseline visit as reported in the eCRF) up to 24 months
Duration of TEAE = (Stop date of TEAE - Start date of TEAE + 1) divided by 7. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of Participants With Therapy Modifications Due to Adverse Event Related to Avelumab Plus Axitinib Therapy
Tidsramme: From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of participants with therapy modifications due to AE related to avelumab plus axitinib therapy were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Number of Participants With Different Types of Medical Intervention or Medications Used for the Management of TEAEs Related to Avelumab Plus Axitinib Therapy
Tidsramme: From index date (baseline visit as reported in the eCRF) up to 24 months after the index date
Number of participants with different types of medical intervention or medications used for the management of TEAE related to avelumab plus axitinib therapy (e.g., use of corticosteroids, antihypertensive therapy, treatment for thyroid dysfunction, measures to decrease hemoglobin, and hematocrit) was reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months after the index date
Percentage of Participants Receiving Later-line Therapy
Tidsramme: From index date (baseline visit as reported in the eCRF) up to 24 months
Percentage of participants receiving later-line therapy were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months
Time to Second-line Therapy Initiation
Tidsramme: Time from Avelumab plus Axitinib therapy discontinuation to the initiation of second-line therapy, assessed up to 24 months
Time to second line treatment was calculated as: (second line treatment start date - last dose of Avelumab plus Axitinib + 1)/30.4375.
Time from Avelumab plus Axitinib therapy discontinuation to the initiation of second-line therapy, assessed up to 24 months
Number of Participants With Patient-reported Potential Signs and Symptoms of Immune-related AEs
Tidsramme: From index date (baseline visit as reported in the eCRF) up to 24 months
Number of participants with patient-reported potential signs and symptoms of immune-related AEs were reported. The index date (baseline visit) was defined as the date of first administration after obtaining informed consent of avelumab plus axitinib therapy to participants with advanced RCC.
From index date (baseline visit as reported in the eCRF) up to 24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Samarbejdspartnere

Merck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

Efterforskere

  • Studieleder: Medical Responsible, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. august 2021

Primær færdiggørelse (Faktiske)

8. august 2024

Studieafslutning (Faktiske)

30. april 2025

Datoer for studieregistrering

Først indsendt

23. juni 2021

Først indsendt, der opfyldte QC-kriterier

23. juni 2021

Først opslået (Faktiske)

28. juni 2021

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

20. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • MS100070_0110

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner